Excitingly, based on the encouraging results of the DESTINY-Lung02 phase II trial, the FDA granted accelerated approval to T-DXd for NSCLC patients harboring HER2 mutations who received systemic therapy on August 11, 2022 [219]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.